Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2017 Sep 22

PMID 28932020

Citations 32

Authors

Francesca Colazzo

Paolo Gelosa

Elena Tremoli

Luigi Sironi

Laura Castiglioni

Affiliations

Soon will be listed here.

Abstract

Cysteinyl leukotrienes (CysLTs) are potent lipid inflammatory mediators synthesized from arachidonic acid, through the 5-lipoxygenase (5-LO) pathway. Owing to their properties, CysLTs play a crucial role in the pathogenesis of inflammation; therefore, CysLT modifiers as synthesis inhibitors or receptor antagonists, central in asthma management, may become a potential target for the treatment of other inflammatory diseases such as the cardiovascular disorders. 5-LO pathway activation and increased expression of its mediators and receptors are found in cardiovascular diseases. Moreover, the cardioprotective effects observed by using CysLT modifiers are promising and contribute to elucidate the link between CysLTs and cardiovascular disease. The aim of this review is to summarize the state of present research about the role of the CysLTs in the pathogenesis and progression of atherosclerosis and myocardial infarction.

Citing Articles

Assessment of Inflammatory and Oxidative Stress Biomarkers for Predicting of Patients with Asymptomatic Carotid Artery Stenosis.

Karaduman A, Ilgin S, Aykac O, Yesilkaya M, Levent S, Ozdemir A J Clin Med. 2025; 14(3).

PMID: 39941424 PMC: 11818673. DOI: 10.3390/jcm14030755.

The Cardioprotective Effects of Polyunsaturated Fatty Acids Depends on the Balance Between Their Anti- and Pro-Oxidative Properties.

Sidorkiewicz M Nutrients. 2024; 16(22).

PMID: 39599723 PMC: 11597422. DOI: 10.3390/nu16223937.

Allergic asthma is a risk factor for human cardiovascular diseases.

Guo J, Zhang Y, Liu T, Levy B, Libby P, Shi G Nat Cardiovasc Res. 2024; 1(5):417-430.

PMID: 39195946 DOI: 10.1038/s44161-022-00067-z.

IL-6 inhibition prevents costimulation blockade-resistant allograft rejection in T cell-depleted recipients by promoting intragraft immune regulation in mice.

Muckenhuber M, Mengrelis K, Weijler A, Steiner R, Kainz V, Buresch M Nat Commun. 2024; 15(1):4309.

PMID: 38830846 PMC: 11148062. DOI: 10.1038/s41467-024-48574-w.

Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects.

Cortellino S, Quagliariello V, Delfanti G, Blazevits O, Chiodoni C, Maurea N Nat Commun. 2023; 14(1):5529.

PMID: 37684243 PMC: 10491752. DOI: 10.1038/s41467-023-41066-3.

References

Sarau H, Ames R, Chambers J, Ellis C, Elshourbagy N, FOLEY J . Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999; 56(3):657-63. DOI: 10.1124/mol.56.3.657. View

Ni N, Yan D, Ballantyne L, Barajas-Espinosa A, St Amand T, Pratt D . A selective cysteinyl leukotriene receptor 2 antagonist blocks myocardial ischemia/reperfusion injury and vascular permeability in mice. J Pharmacol Exp Ther. 2011; 339(3):768-78. DOI: 10.1124/jpet.111.186031. View

Piomelli D, Feinmark S, Cannon P . Leukotriene biosynthesis by canine and human coronary arteries. J Pharmacol Exp Ther. 1987; 241(3):763-70. View

Back M . Functional characteristics of cysteinyl-leukotriene receptor subtypes. Life Sci. 2002; 71(6):611-22. DOI: 10.1016/s0024-3205(02)01733-2. View

Paruchuri S, Jiang Y, Feng C, Francis S, Plutzky J, Boyce J . Leukotriene E4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D2 generation by human mast cells. J Biol Chem. 2008; 283(24):16477-87. PMC: 2423236. DOI: 10.1074/jbc.M705822200. View

Peters-Golden M, Henderson Jr W . Leukotrienes. N Engl J Med. 2007; 357(18):1841-54. DOI: 10.1056/NEJMra071371. View

Brink C, Dahlen S, Drazen J, Evans J, Hay D, Nicosia S . International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev. 2003; 55(1):195-227. DOI: 10.1124/pr.55.1.8. View

Koller M, SCHONFELD W, Knoller J, Bremm K, Konig W, Spur B . The metabolism of leukotrienes in blood plasma studied by high-performance liquid chromatography. Biochim Biophys Acta. 1985; 833(1):128-34. DOI: 10.1016/0005-2760(85)90260-7. View

Kitagawa K, Matsumoto M, Hori M . Cerebral ischemia in 5-lipoxygenase knockout mice. Brain Res. 2004; 1004(1-2):198-202. DOI: 10.1016/j.brainres.2004.01.018. View

10.

Soder P, Soder B, Nowak J, Jogestrand T . Early carotid atherosclerosis in subjects with periodontal diseases. Stroke. 2005; 36(6):1195-200. DOI: 10.1161/01.STR.0000165916.90593.cb. View

11.

Hahn R, MacDonald B, Morgan E, Potts B, Parli C, Rinkema L . Evaluation of LY203647 on cardiovascular leukotriene D4 receptors and myocardial reperfusion injury. J Pharmacol Exp Ther. 1992; 260(3):979-89. View

12.

Folco G, Rossoni G, Buccellati C, Berti F, Maclouf J, Sala A . Leukotrienes in cardiovascular diseases. Am J Respir Crit Care Med. 2000; 161(2 Pt 2):S112-6. DOI: 10.1164/ajrccm.161.supplement_1.ltta-22. View

13.

Burke J, Levi R, Guo Z, Corey E . Leukotrienes C4, D4 and E4: effects on human and guinea-pig cardiac preparations in vitro. J Pharmacol Exp Ther. 1982; 221(1):235-41. View

14.

Maekawa A, Kanaoka Y, Xing W, Austen K . Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci U S A. 2008; 105(43):16695-700. PMC: 2575482. DOI: 10.1073/pnas.0808993105. View

15.

Ingelsson E, Yin L, Back M . Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012; 129(3):702-707.e2. DOI: 10.1016/j.jaci.2011.11.052. View

16.

Dahlen S . Treatment of asthma with antileukotrienes: first line or last resort therapy?. Eur J Pharmacol. 2006; 533(1-3):40-56. DOI: 10.1016/j.ejphar.2005.12.070. View

17.

Flens M, Zaman G, van der Valk P, Izquierdo M, Schroeijers A, Scheffer G . Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996; 148(4):1237-47. PMC: 1861521. View

18.

Walch L, Norel X, Gascard J, Brink C . Functional studies of leukotriene receptors in vascular tissues. Am J Respir Crit Care Med. 2000; 161(2 Pt 2):S107-11. DOI: 10.1164/ajrccm.161.supplement_1.ltta-21. View

19.

Mueller C, Wassmann K, Widder J, Wassmann S, Hui Chen C, Keuler B . Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation. 2008; 117(22):2912-8. DOI: 10.1161/CIRCULATIONAHA.107.747667. View

20.

Nobili E, Salvado M, Folkersen L, Castiglioni L, Kastrup J, Wetterholm A . Cysteinyl leukotriene signaling aggravates myocardial hypoxia in experimental atherosclerotic heart disease. PLoS One. 2012; 7(7):e41786. PMC: 3404957. DOI: 10.1371/journal.pone.0041786. View